ABCMdb

ABCC8 p.Leu210Trp

None has been submitted yet.

Publications

PMID: 17514016 [PubMed] Costagliola D et al: "Prevalence of HIV-1 drug resistance in treated patients: a French nationwide study."

No. Sentence Comment

54 NRTI resistance mutations selected by thymidine analogues (M41L, D67N, L210W, and T215Y/F) were also present frequently, whereas K70R and K219Q/E were present much less frequently. Login to comment

PMID: 18462814 [PubMed] Poonpiriya V et al: "A study of seven rule-based algorithms for the interpretation of HIV-1 genotypic resistance data in Thailand."

No. Sentence Comment

72 Among 668 (96.7%) other patients infected with non-B HIV-1 variants, the subtype/CRF distribution in decreasing order Table 1 Prevalence of pol gene mutation associated with antiretroviral drug resistance for NRTIs, NNRTIs and PIs in comparison to the total population and two major subtypes (CRF01 AE and B) Mutation RT HIV Total (721) numbers (%) Subtype B (n = 53) numbers (%) CRF01 AE (n = 640) numbers (%) p-Value NRTIs M41L 195(27%) 7(13%) 182(28%) 0.016a E44D 62(9%) 3(6%) 54(8%) 0.61 A62V 22(3%) 4(8%) 17(3%) 0.069 K65R 34(5%) 6(11%) 26(4%) 0.029a D67N 299(42%) 18(34%) 271(42%) 0.25 T69D 36(5%) 3(6%) 30(5%) 0.733 INS69 3(1%) 0(0%) 1(0.2%) 1 K70R 187(26%) 10(19%) 170(27%) 0.256 L74V 38(5%) 5(9%) 32(5%) 0.192 V75I 23(3%) 3(6%) 18(3%) 0.212 F77L 14(2%) 3(6%) 9(1%) 0.057 Y115F 11(2%) 5(9%) 6(1%) 0.001a F116Y 26(4%) 3(6%) 21(3%) 0.419 V118I 138(19%) 8(15%) 124(19%) 0.585 Q151M 36(5%) 4(8%) 30(5%) 0.32 M184V/I 297(41%) 22(42%) 269(42%) 1 L210W 150(21%) 7(13%) 134(21%) 0.215 T215F/Y 283(39%) 15(28%) 257(40%) 0.107 K219Q/E 184(26%) 12(23%) 168(26%) 0.628 NNRTIs L1001 17(2%) 2(4%) 16(3%) 0.641 K103N 161(22%) 10(19%) 145(23%) 0.609 V106A/M 20(3%) 2(4%) 15(2%) 0.378 V108I 61(8%) 5(9%) 54(8%) 0.797 Y181C/I 121(17%) 9(17%) 108(17%) 1 Y188C/L/H 41(6%) 2(4%) 39(6%) 0.761 G190A/S 128(18%) 7(13%) 118(18%) 0.457 P225H 27(4%) 0(0%) 26(4%) 0.251 M230L 10(1%) 1(2%) 9(1%) 0.551 Protease L10F/I/R/V 6(1%) 2(4%) 2(0.3%) 0.031 K20M/R/I/T 3(1%) 1(2%) 0(0%) 0.076 L33F/I/V 4(1%) 2(4%) 1(0.2%) 0.016a M36I/L/V 88(12%) 2(4%) 94(15%) 0.022a M46I/L 39(5%) 0(0%) 32(5%) 0.163 I47V/A 1(1%) 0(0%) 1(0.2%) 1 G48V 17(2%) 2(4%) 13(2%) 0.32 F53L 11(2%) 0(0%) 11(2%) 1 I54VL/M/T/S 37(5%) 4(8%) 30(5%) 0.32 L63P 183(25%) 33(62%) 140(22%) 0a A71V/T 34(5%) 12(23%) 17(3%) 0a G73A/C/S/T 4(1%) 2(4%) 1(0.2%) 0.016a V82A/T/F/S 37(5%) 3(6%) 33(5%) 0.531 I84V 8(1%) 1(2%) 6(1%) 0.428 N88D/S 12(2%) 3(6%) 7(1%) 0.035a L90M 35(5%) 8(15%) 26(4%) 0.003a a Marker indicates the statistically significant difference between subtypes calculated by Fisher`s exact test. Login to comment
80 The frequency of Multi-NRTI resistance mutations for the thymidine analog or TAMs (M41L, D67N, K70R, L210W, T215F/Y) was detected in about 6 (0.8%) from the overall population, and presented with all five mutations shown; and 159 (22%) gave the highest frequency, containing at least two mutations associated with TAMs (D67N and K70R). Login to comment
123 In particularly, the frequencies of co-appearance TAM members (M41L, D67N, K70R, L210W, T215F/Y) were commonly prevalent in CRF01 AE when compared to the B subtype. Login to comment

PMID: 19320592 [PubMed] Kouanfack C et al: "Low levels of antiretroviral-resistant HIV infection in a routine clinic in Cameroon that uses the World Health Organization (WHO) public health approach to monitor antiretroviral treatment and adequacy with the WHO recommendation for second-line treatment."

No. Sentence Comment

54 Variable Month 12 (n p 249) Month 24 (n p 178) Mutations associated with NRTI resistance f T215Y 1 1 M41L, D67N, L210W, T215Y 1 … M41L, T215FY … 2 M41L L74V, T215Y … 1 D67N, K70R, K219Q … 1 D67N, K70R, K219E … 1 D67N, K70R, T215Y, K219Q … 1 M184V 10 27 Resistance after treatment switcha 2/20 (10.0) 3/16 (18.8) Resistance after treatment interruptionb 0/10 14/24 (58.3) NOTE. Login to comment